Jazz Pharmaceuticals reports Q2 adjusted EPS ($8.25), consensus ($6.25)

Reports Q2 revenue $1.045B, consensus $1.05B. “It has been a privilege to lead Jazz over my 22-year tenure. I am proud of what we have achieved on behalf of patients and confident that our new President and CEO, Renee Gala, will build on Jazz’s momentum and serve as a catalyst in driving long-term growth,” said Bruce Cozadd, chairman and chief executive officer, Jazz Pharmaceuticals (JAZZ). “We continue to see significant opportunity across our diversified portfolio in sleep, epilepsy, and oncology, as evidenced by the strong performance this quarter from our sleep portfolio with robust continued growth from Xywav in both narcolepsy and IH. We remain confident in the outlook of the business driven by multiple anticipated near-term oncology catalysts that each represent significant opportunities to drive greater revenue and create long-term value, most notably the top-line data readout for zanidatamab from the HERIZON-GEA-01 trial and upcoming PDUFA dates for dordaviprone and Zepzelca.”